Atrion Co. (NASDAQ:ATRI) has received an average broker rating score of 5.00 (Strong Sell) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong sell recommendation.
Analysts have set a one year consensus target price of $300.00 for the company, according to Zacks. Zacks has also assigned Atrion an industry rank of 222 out of 255 based on the ratings given to its competitors.
Separately, BidaskClub raised shares of Atrion from a “strong sell” rating to a “sell” rating in a report on Thursday, June 21st.
Atrion (NASDAQ:ATRI) last issued its earnings results on Tuesday, August 7th. The medical instruments supplier reported $4.70 earnings per share (EPS) for the quarter. Atrion had a net margin of 22.57% and a return on equity of 17.99%. The business had revenue of $38.85 million for the quarter.
The firm also recently announced a quarterly dividend, which was paid on Friday, September 28th. Shareholders of record on Friday, September 14th were issued a dividend of $1.35 per share. This is a boost from Atrion’s previous quarterly dividend of $1.20. The ex-dividend date was Thursday, September 13th. This represents a $5.40 dividend on an annualized basis and a yield of 0.79%.
Hedge funds have recently modified their holdings of the business. Xact Kapitalforvaltning AB bought a new position in shares of Atrion in the first quarter worth $248,000. Principal Financial Group Inc. bought a new position in shares of Atrion in the first quarter worth $249,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new position in shares of Atrion in the second quarter worth $240,000. Chevy Chase Trust Holdings Inc. bought a new position in shares of Atrion in the second quarter worth $300,000. Finally, Bank of Montreal Can bought a new position in shares of Atrion in the second quarter worth $362,000. 61.11% of the stock is currently owned by institutional investors and hedge funds.
Atrion Company Profile
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Featured Story: Why is insider trading harmful?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.